EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study

Tim Rowland iD, Richard FitzGerald iD, Elizabeth Challenger iD, Laura Dickinson iD, Laura J Else iD, Lauren Walker iD, Colin Hale, Victoria Shaw iD, Callum Kelly, Rebecca Lyon, Jennifer Gibney, Karim Dhamani und 21 weitere

Clinical Pharmacology & Therapeutics · 2026-06 · 119 (6) · 1650-1661

DOI: 10.1002/cpt.70261 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 18.03.2026. Verfasst von Tim Rowland und 32 weiteren Autor:innen. Beteiligte Einrichtung: Liverpool School of Tropical Medicine, Liverpool, UK. Hauptthemen laut MEDLINE: Amides, Antiviral Agents, COVID-19 Drug Treatment, Pyrazines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Food and Drug Administration, National Institute for Health and Care Research, National Institute for Health Research Southampton Biomedical Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AGILE (NCT04746183) is a Phase Ib/IIa platform, evaluating candidates to treat COVID‐19. Candidate Specific Trial 6 evaluated the safety and optimal dose of a novel intravenous formulation of favipiravir in a dose‐escalating, open‐label, randomized, controlled, Bayesian adaptive Phase Ib trial. Hospitalized adults with PCR‐confirmed SARS‐CoV‐2 infection, within 14 days of symptomatic COVID‐19 were randomized 2:1 in groups of 6 ( n = 4 favipiravir, n = 2 standard of care) to ascending doses of intravenous favipiravir twice daily (b.i.d.) for 7 days or standard of care. Clinical data, safety evaluations, virology and pharmacokinetic samples were collected. The primary outcome was safety. Secondary outcomes included clinical, pharmacokinetic and virological endpoints. Twenty‐four participants enrolled between September 10, 2022 and November 1, 2023 [10/24 female; median age 74 years (range 52–93)]. Favipiravir was well tolerated despite a high background rate of unrelated adverse events. No dose limiting toxicities were observed, with a model‐predicted dose limiting toxicity risk of 16.8% and probability of unacceptable toxicity of 2.7% at the highest dose level. No serious adverse events were deemed related to favipiravir but an expected association with asymptomatic, transient hyperuricemia was observed. Favipiravir exposures increased disproportionally to dose with significant accumulation in plasma, but with marked variability between participants within each cohort. This novel formulation of favipiravir was safe at sustained high doses that reached pre‐specified pharmacokinetic targets in a study group with frailty and complex health profiles. We consider doses up to 2,400 mg b.i.d. to be safe for further evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmidesAntiviral AgentsCOVID-19 Drug TreatmentPyrazinesAgedAged, 80 and overFemaleHumansMaleMiddle AgedAdministration, IntravenousBayes TheoremCOVID-19Dose-Response Relationship, DrugHospitalizationSARS-CoV-2

Substanzen

AmidesAntiviral AgentsfavipiravirPyrazines

Autor:innen und Institutionen

  • Liverpool School of Tropical Medicine, Liverpool, UK.
  • Liverpool University Hospitals Foundation Trust, Liverpool, UK.
  • NIHR Liverpool Clinical Research Facility, Liverpool, UK.
  • Department of Pharmacology and Therapeutics, Institute of Integrative, Systems and Molecular Biology, Centre for Experimental Therapeutics (TherEx), University of Liverpool, Liverpool, UK.
  • PHARMExcel, Welwyn Garden City, UK.
  • Bangor University, Bangor, UK.

ORCID-Profile: Tim Rowland, Richard FitzGerald, Elizabeth Challenger, Laura Dickinson, Laura J Else, Lauren Walker, Victoria Shaw, Michelle Tetlow, William Wood, Helen Reynolds, Justin Chiong, Orod Osanlou, Henry Pertinez, Katie Bullock, William Greenhalf, Andrew Owen, David G Lalloo, Julian A Hiscox, Thomas Jaki, Pavel Mozgunov, Geoffrey Saunders, Gareth Griffiths, Saye H Khoo, Thomas E Fletcher

Förderung

  • US Food and Drug Administration
  • National Institute for Health and Care Research
  • National Institute for Health Research Southampton Biomedical Research Centre
  • Medical Research Council
  • Wellcome Trust
  • U.S. Food and Drug Administration

Zitieren

APA

Rowland, T., FitzGerald, R., Challenger, E., Dickinson, L., Else, L. J., Walker, L., Hale, C., Shaw, V., Kelly, C., Lyon, R., Gibney, J., Dhamani, K., Irwin, M., Enever, Y., Tetlow, M., Wood, W., Reynolds, H., Chiong, J., Osanlou, O., …, & AGILE CST‐6 Study Group (2026). Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study. Clinical Pharmacology & Therapeutics, 119(6), 1650-1661. https://doi.org/10.1002/cpt.70261

Vancouver

Rowland T, FitzGerald R, Challenger E, Dickinson L, Else LJ, Walker L, et al. Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study. Clinical Pharmacology & Therapeutics. 2026;119(6):1650-1661. doi:10.1002/cpt.70261

BibTeX
@article{Rowland2026,
  author = {Rowland, Tim and FitzGerald, Richard and Challenger, Elizabeth and Dickinson, Laura and Else, Laura J and Walker, Lauren and Hale, Colin and Shaw, Victoria and Kelly, Callum and Lyon, Rebecca and Gibney, Jennifer and Dhamani, Karim and Irwin, Margaret and Enever, Yvanne and Tetlow, Michelle and Wood, William and Reynolds, Helen and Chiong, Justin and Osanlou, Orod and Pertinez, Henry and Bullock, Katie and Greenhalf, William and Owen, Andrew and Lalloo, David G and Jacobs, Michael and Hiscox, Julian A and Jaki, Thomas and Mozgunov, Pavel and Saunders, Geoffrey and Griffiths, Gareth and Khoo, Saye H and Fletcher, Thomas E and AGILE CST‐6 Study Group, AGILE CST‐6 Study Group},
  title = {Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID ‐19: A Dose‐Escalating, Randomized Controlled Phase Ib Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {119},
  number = {6},
  pages = {1650--1661},
  doi = {10.1002/cpt.70261}
}
Kostenlos starten →